TRIM6 silencing for inhibiting growth and angiogenesis of gliomas by regulating VEGFA

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Research

Background:

• Gliomas are aggressive primary central nervous system (CNS) cancers with limited treatment options.
• Identifying novel molecular targets is crucial for improving glioma patient outcomes.
• The role of Tripartite Motif Protein 6 (TRIM6) in glioma pathogenesis requires further investigation.

Purpose of the Study:

• To investigate the expression and functional role of TRIM6 in glioma.
• To elucidate the molecular mechanisms underlying TRIM6's influence on glioma progression.
• To evaluate TRIM6 as a potential therapeutic target for glioma.

Main Methods:

• Analysis of TRIM6 expression in public glioma databases.
• In vitro experiments involving TRIM6 knockdown in glioma cells.
• Assessment of cell proliferation, migration, and angiogenesis.
• Western blot analysis to determine protein expression levels (FOXM1, VEGFA).
• In vivo xenograft mouse model to evaluate TRIM6's effect on tumor growth.

Main Results:

• Increased TRIM6 expression was observed in glioma tissues and correlated with poorer overall survival.
• TRIM6 silencing inhibited glioma cell proliferation, migration, and angiogenesis.
• Knockdown of TRIM6 led to decreased expression of Forkhead Box M1 (FOXM1) and Vascular Endothelial Growth Factor A (VEGFA).
• TRIM6's effect on VEGFA was mediated by FOXM1.
• VEGFA overexpression rescued the inhibitory effects of TRIM6 silencing.
• TRIM6 promoted glioma growth in a xenograft mouse model.

Conclusions:

• Elevated TRIM6 expression is associated with poor prognosis in glioma patients.
• TRIM6 promotes glioma cell proliferation, migration, and angiogenesis via the FOXM1-VEGFA signaling pathway.
• TRIM6 represents a promising novel therapeutic target for clinical intervention in glioma treatment.